首页> 美国卫生研究院文献>other >Multi-layered nanoparticles for combination gene and drug delivery to tumors
【2h】

Multi-layered nanoparticles for combination gene and drug delivery to tumors

机译:多层纳米颗粒可将基因和药物联合运用于肿瘤

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Drug resistance and toxicity are major obstacles in cancer chemotherapy. Combination therapies can overcome resistance, and synergies can minimize dosing. Polymer nanocarriers are interesting vehicles for cancer therapeutics for their delivery and tumor targeting abilities. We synthesized a multilayered polymer nanoparticle (MLNP), comprising of poly(lactic-co-glycolic acid) with surface polyethyleneimine and functional peptides, for targeted drug and gene delivery. We confirmed the particle’s ability to inhibit tumor growth through synergistic action of the drug and gene product. MLNPs achieved transfection levels similar to lipofectamine, while maintaining minimal cytotoxicity. The particles delivered camptothecin (CPT), and plasmid encoding TNF related apoptosis inducing ligand (pTRAIL) (CT MLNPs), and synergistically inhibited growth of multiple cancer cells in vitro. The synergy of co-delivering CPT and pTRAIL via CT MLNPs was confirmed using the Chou-Talalay method: the combination index (CI) values at 50% inhibition ranged between 0.31–0.53 for all cell lines. Further, co-delivery with MLNPs resulted in a 3.1–15 fold reduction in CPT and 4.7–8.0 fold reduction in pTRAIL dosing. CT MLNPs obtained significant HCT116 growth inhibition in vivo compared to monotherapy. These results support our hypothesis that MLNPs can deliver both small molecules and genetic agents towards synergistically inhibiting tumor growth.
机译:耐药性和毒性是癌症化学疗法的主要障碍。组合疗法可以克服耐药性,并且协同作用可以使剂量最小化。聚合物纳米载体因其递送和靶向肿瘤的能力而成为用于癌症治疗的有趣载体。我们合成了多层聚合物纳米粒子(MLNP),其中包括聚(乳酸-乙醇酸共聚物)与表面聚乙烯亚胺和功能性肽,用于靶向药物和基因递送。我们证实了该颗粒具有通过药物和基因产物的协同作用抑制肿瘤生长的能力。 MLNPs达到与lipofectamine相似的转染水平,同时保持最小的细胞毒性。颗粒传递喜树碱(CPT)和编码TNF相关凋亡诱导配体(pTRAIL)(CT MLNPs)的质粒,并在体外协同抑制多种癌细胞的生长。使用Chou-Talalay方法证实了通过CT MLNPs共同递送CPT和pTRAIL的协同作用:对于所有细胞系,在50%抑制率下的组合指数(CI)值在0.31-0.53之间。此外,与MLNPs共同交付导致CPT减少3.1–15倍,pTRAIL剂量减少4.7–8.0倍。与单一疗法相比,CT MLNPs在体内获得了显着的HCT116生长抑制作用。这些结果支持了我们的假设,即MLNP可以传递小分子和遗传因子,从而协同抑制肿瘤的生长。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号